Xavier Montalban, MD, PhD, BA, Vall d’Hebron University Hospital, Barcelona, Spain, discusses work on the natural history of multiple sclerosis (MS) and how it progresses from its early stages. For the past 30 years, two active, prospective cohorts of clinically isolated syndrome (CIS) patients and treated MS patients have been thoroughly investigated from imaging and biological perspectives. Prof. Montalban states that this has resulted in abundant data concerning diagnostic criteria, treatment response, and prognostic factors for patients with MS. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Dr Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.